Search the Newsreel

Omnicell (OMCL) Reports Q2: Everything You Need To Know Ahead Of Earnings

Omnicell (OMCL) is set to announce its Q2 earnings this Thursday morning. The company previously exceeded revenue expectations, reporting $309.9 million, a 14.9% year-on-year increase, and beat analysts' EPS estimates. For the upcoming quarter, the market anticipates a 6.8% year-on-year revenue growth, and analysts …

Omnicom Group Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:OMC) 2026-07-29

Omnicom Group Inc. published its Q2 2026 earnings call presentation, reporting an EPS of $2.65, missing estimates by $0.01. The company's revenue reached $6.56 billion, beating expectations by $105.05 million and showing a significant 63.43% year-over-year increase. This article provides access to the slide …

Omnicom targets 4.5%-5% 2026 organic growth while advancing $900M synergies and completing $5B buyback by Q1 2027

Earnings Call Insights: Omnicom Group Inc. (OMC) Q2 2026 MANAGEMENT VIEW * "Starting with revenue from Core Operations... we achieved organic growth of 6.1% in the second quarter" and "Ongoing or Core Operations adjusted EBITA growth was 20.4%" with "EBITA margin" up "almost 200 …

Omnicell (OMCL) Could Be 30% Undervalued If Its OmniSphere Shift Pays Off

Omnicell (OMCL) is attracting attention due to recent share price movements and its strategic shift towards the cloud-native OmniSphere platform, which aims to simplify medication management and boost recurring SaaS-based revenues. While a popular narrative suggests the company is 29.8% undervalued with a fair …

Earnings call transcript: Omnicom tops Q2 2026 estimates, raises outlook

Omnicom Group reported strong second-quarter 2026 results, exceeding Wall Street expectations with adjusted earnings of $2.65 per share and $6.6 billion in revenue. The company benefited from the Interpublic Group acquisition and cost-reduction synergies, leading to a 6.1% organic revenue rise in core operations …

Omnicom (OMC) Tops Q2 Earnings and Revenue Estimates

Omnicom (OMC) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Omnicom Group (NYSE:OMC) Beats Q2 CY2026 Sales Expectations But Stock Drops

Omnicom Group reported Q2 CY2026 results, exceeding Wall Street's revenue expectations with sales up 63.4% year-on-year to $6.56 billion. However, despite beating revenue forecasts and maintaining a strong adjusted EPS, its stock dropped 6.5% to $80.60 immediately after the announcement, indicating the market was …

Omnicom: Q2 Earnings Snapshot

The provided content is a very short snippet related to Omnicom and its Q2 earnings, but it lacks any actual article text or financial information. It seems to be an incomplete or placeholder content.

Omnicom falls 2% despite beating second quarter estimates

Omnicom Group Inc. (NYSE:OMC) exceeded analyst expectations for its second-quarter results, with adjusted EPS of $2.65 and revenue of $6.6 billion. Despite this strong performance and a 4.7% gain during the regular session, the company's shares declined 2% in after-hours trading. The growth was …

Earnings Flash (OMC) Omnicom Group Inc. Reports Q2 Revenue $6.56B, vs. FactSet Est of $6.44B

Omnicom Group Inc. announced its Q2 revenue of $6.56 billion, surpassing the FactSet estimate of $6.44 billion. This financial update indicates a stronger-than-expected performance for the advertising and marketing giant in the second quarter. The company's results were published on July 28, 2026.

Omnicom's Core Revenue Reaches $6.0B With 6.1% Organic Growth

Omnicom (NYSE: OMC) reported a strong second quarter in 2026, with core operations revenue hitting $6.0 billion, driven by a 6.1% organic growth and a 1.1% foreign currency benefit. The company's Adjusted EBITA rose to $1.07 billion, pushing the margin to 17.8%, mainly due …

Global Indemnity Group Q2 2026 Earnings Release & Conference Call

WILMINGTON, Del., July 28, 2026 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (NASDAQ:GBLI) (“GBLI”) announced today that it will release its second quarter 2026 earnings results before market open on Wednesday, August 5, 2026. GBLI will hold an earnings call to discuss second quarter …

Omnicom Reports Second Quarter 2026 Results

Omnicom (OMC) has announced strong second-quarter 2026 results, with revenue in its Core Operations growing 6.1% organically to $6.0 billion and a notable expansion in Non-GAAP Adjusted EBITA margin to 17.8%. The company reported diluted earnings per share of $2.08, or $2.65 non-GAAP adjusted, …

Why Omnicom Group (OMC) Stock Is Up Today

Omnicom Group (OMC) stock is up 4.7% today, likely due to investor anticipation ahead of its Q2 2026 earnings release. Optimism is also fueled by higher-than-expected cost synergies from its Interpublic combination and a significant share repurchase program. The article also provides details on …

Earnings Flash (OMC) Omnicom Group Inc. Posts Q2 Adjusted EPS $2.65 per Share, vs. FactSet Est of $2.67

Omnicom Group Inc. (OMC) reported its Q2 adjusted EPS at $2.65 per share, which fell slightly short of the FactSet estimate of $2.67. The company's Q2 revenue was $6.56 billion, surpassing FactSet's estimate of $6.44 billion. The earnings flash highlights the company's financial performance …

Omnicom set to report earnings as mega-merger execution scrutinized

Omnicom Group Inc. is reporting second-quarter earnings, with investors keenly watching its execution of the Interpublic acquisition, particularly concerning integration progress, synergy targets, and client retention. Analysts anticipate significant year-over-year growth in EPS and revenue, largely driven by the acquisition. The focus will also …

Omnicom Group stock hits 52-week high at 87.17 USD By Investing.com

Omnicom Group's stock reached a new 52-week high of $87.17, currently trading at $87.18 with a market capitalization of $24.79 billion. InvestingPro analysis suggests the stock is undervalued, offering a 3.88% dividend yield and having maintained dividend payments for 56 consecutive years. This milestone …

(AMN) Risk Channels and Responsive Allocation

This article provides a detailed AI-driven stock analysis for Amn Healthcare Services Inc (NYSE: AMN), highlighting weak near-term sentiment despite long-term strength. It outlines specific trading strategies categorized by risk profile and holding period, including position, momentum breakout, and risk hedging strategies. The analysis …

Are Business Services Stocks Lagging AMN Healthcare Services (AMN) This Year?

For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. AMN Healthcare Services (AMN) is a stock that can certainly grab the attention of many investors, but do its recent …

Global Indemnity Group Q2 Results: Earnings call set for Aug 5

MNTN (MNTN) Expected to Post Quarterly Earnings on Tuesday

Vuzix (VUZI) investor group led by AIGH discloses 6.7M-share stake

An investor group led by AIGH Capital Management LLC has disclosed an 8.1% stake in Vuzix Corporation (VUZI), holding 6,745,667 shares of common stock. The filing, a Schedule 13G, indicates that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman collectively possess …

Enterprise value to EBIT forward of OmniAb, Inc. – NASDAQ:OABI

This article focuses on the enterprise value to EBIT forward for OmniAb, Inc. (NASDAQ:OABI). It indicates that financial data for this metric is provided by FactSet Research Systems Inc. and market data by ICE Data Services.

(OMC) and the Role of Price-Sensitive Allocations

This article provides an in-depth analysis of Omnicom Group Inc. (NYSE: OMC) focusing on price-sensitive allocations, neutral sentiment, and potential trading strategies. It highlights an exceptional risk-reward short setup and offers AI-generated signals and institutional trading strategies for various risk profiles. The analysis suggests …

Amneal Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMRX

OMC Looks 12.9% Undervalued on GF Value™ Heading into Q2 Earnings

Omnicom Group Inc (NYSE: OMC) is preparing to announce its second-quarter earnings, with analysts forecasting significant increases in EPS and revenue. GuruFocus' GF Value™ suggests the stock is modestly undervalued by 12.9%, despite a high trailing P/E ratio, while its GF Score™ of 83 …

AMN Healthcare Services Inc (AMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of AMN Healthcare Services Inc (AMN), detailing its price momentum score of 3.58 and its trading range between a resistance of $36.20 and support of $30.78. It presents a breakdown of various technical indicators, such as MACD, RSI, …

Somnigroup Announces Refinancing of Credit Facilities

Somnigroup International Inc. announced the successful refinancing of its $2.9 billion senior secured credit facilities, including a $1.7 billion revolver and a $1.2 billion term loan A. This amendment lowers the company's cost of capital, extends debt maturities, and enhances financial flexibility. The transaction …

Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone

Veraxa Biotech has advanced its bispecific antibody-drug conjugate (ADC) program, VXA-222, into the next development phase after OmniAb completed its antibody discovery work. This collaboration utilizes OmniAb's transgenic antibody discovery platform and Veraxa’s proprietary ADC linker and conjugation technology to create a dual-antigen "AND-gate" …

VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate (bsADC) program, VXA-222, reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). OmniAb completed its discovery work, moving the program to its next phase. VXA-222 is designed to target two tumor …

AMN Healthcare Services Inc (AMN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AMN Healthcare Services Inc (AMN), detailing its volatility, financial, and investment risks. The company currently holds a risk assessment score of 5.69, positioning it at 35 out of 75 in the Healthcare Providers & Services industry. Key …

Omnicom Group Inc (OMC) Balance Sheet

This article provides a detailed balance sheet for Omnicom Group Inc (OMC), outlining quarterly and annual financial data across various asset, liability, and equity categories. It includes historical data dating back several years, showing trends in cash, receivables, total assets, total liabilities, and shareholders' …

How marketers can tackle a new creative paradigm with connected content

Marketers are facing a new creative paradigm called "connected content" due to media fragmentation, second screening, and AI. This model, proposed by Omnicom Media Intelligence, aims to integrate various channels like media, commerce, and creator marketing into content creation for more effective campaigns. It …

Erie Indemnity (ERIE) director gains 1.762 deferred compensation share credits

Erie Indemnity Company director William David Edwards acquired 1.762 Directors' Deferred Compensation Share Credits on July 21, 2026, through dividend reinvestment. These share credits represent the right to receive an equivalent number of Class A common shares upon the termination of his board service …

OABI|OmniAb Inc|Price:2.030|

OmniAb Inc. (OABI) licenses discovery research technology to pharmaceutical and biotech companies, leveraging its OmniAb platform to identify optimal antibodies for drug development. The company utilizes engineered transgenic animals like OmniRat and OmniChicken to generate human sequence antibodies. OmniAb's top five shareholders include Mr. …

Veraxa advances cancer therapy program with OmniAb

Veraxa Biotech AG announced that its bispecific antibody-drug conjugate program, VXA-222, advanced to the next development phase after completing discovery work with OmniAb, Inc. The program targets solid tumors using AND-gate logic, combining OmniAb's antibody discovery technologies with Veraxa's linker technology. Veraxa holds exclusive …